Read More: Olympic decathlete Kevin Mayer says the best diet for you isn’t about calories, it’s about something written in your genes<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nXiaqing Jiang and senior researcher Kristine Yaffe of the University of California, San Francisco<\/a>, examined blood markers connected to amyloid and tau. These are proteins that can build up abnormally in the brain during Alzheimer\u2019s disease.<\/p>\n\n\n\nAbout 6% of the participants had high levels of both types of markers. Those people were still living independently and did not have diagnosable cognitive impairment, but their test results revealed small differences in certain thinking skills.<\/p>\n\n\n\n
Memory risks rose sharply<\/h2>\n\n\n\n
Participants with Alzheimer\u2019s-linked blood markers were more likely to have difficulty with verbal memory, which is the ability to learn and remember words. They also showed differences in processing speed and executive function, skills used when reacting to changing information, organizing a schedule, or managing household finances.<\/p>\n\n\n\n
One amyloid-related marker was associated with more than four times the risk of verbal memory problems. In practical terms, an estimated risk of about three cases in every 100 people could rise to roughly 12 in every 100 among those who tested positive.<\/p>\n\n\n\n
That is a meaningful increase, but it is not a diagnosis. Some people with abnormal proteins may never develop Alzheimer\u2019s dementia, while others may decline years later.<\/p>\n\n\n\n
\u201cAlzheimer\u2019s disease pathology begins years before symptoms emerge,\u201d Yaffe said in a UCSF report. Detecting the process sooner could give people more time to address health factors that may influence dementia risk.<\/p>\n\n\n\n![\"Family](\"https:\/\/okdiario.com\/metabolic\/en\/wp-content\/uploads\/2026\/07\/alzheimers-early-detection-family-support-memory-care.jpg\" "\\"\\"")
Early detection of Alzheimer’s disease could help families plan care sooner, as researchers investigate blood tests that identify the disease before symptoms appear.<\/figcaption><\/figure>\n\n\n\nWhat these proteins mean<\/h2>\n\n\n\n
Amyloid is a protein that can form sticky plaques between brain cells. Tau normally helps support the internal structure of those cells, but damaged tau can twist into tangles and interfere with their ability to function.<\/p>\n\n\n\n
\n\n\nRead More: A woman ignored the warning signs for years, then a low-carb diet did something to her type-2 diabetes that surprised her doctors<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nThink of amyloid as debris beginning to collect along a road. Tau is more closely connected to the traffic breakdown that follows as brain cells become damaged and communication slows.<\/p>\n\n\n\n
These changes may begin many years before someone repeatedly loses keys, forgets appointments, or struggles to follow a familiar conversation. That long silent period is why researchers are searching for simple tests that can detect trouble earlier.<\/p>\n\n\n\n
A more sensitive brain scan<\/h2>\n\n\n\n
A second Lancet study<\/a> compared two radioactive tracers used during positron emission tomography, commonly called PET imaging. Tracers attach to specific proteins and allow a scanner to show where those proteins have accumulated in the brain.<\/p>\n\n\n\nResearchers led by Tharick Pascoal examined 682 participants at eight sites in the United States and Canada. Each person received scans using the established tracer flortaucipir and the experimental tracer MK-6240.<\/p>\n\n\n\n
Among cognitively healthy people who already had amyloid buildup, MK-6240 detected tau in about 15%. The standard tracer found it in about 6%, suggesting that the newer method may reveal Alzheimer\u2019s-related changes at an earlier stage.<\/p>\n\n\n\n
Why earlier detection matters<\/h2>\n\n\n\n
Current testing can involve expensive brain imaging or a lumbar puncture, which collects fluid from around the spinal cord. Blood tests would be faster, less invasive, and easier to use in regular clinics.<\/p>\n\n\n\n
Earlier identification<\/a> could also help doctors decide who may benefit from lecanemab<\/a> or donanemab<\/a>. These drugs do not cure Alzheimer\u2019s or restore memories already lost, but clinical trials indicate that they can modestly slow decline when given during the disease\u2019s early stages.<\/p>\n\n\n\nTiming matters. Once extensive brain damage has occurred, removing some amyloid may offer far less benefit. That is why the search for an early warning test has become one of the field\u2019s biggest priorities.<\/p>\n\n\n\n
Screening carries real risks<\/h2>\n\n\n\n
Should every healthy adult get tested? For now, many specialists say no.<\/p>\n\n\n\n
The main problem is uncertainty. Alzheimer\u2019s-linked proteins are relatively uncommon in healthy middle-aged people, and a test could produce false positives or identify people who would never experience serious cognitive decline.<\/p>\n\n\n\n
\n\n\nRead More: Scientists studied 49 pairs of identical twins and found a single immune switch that may decide whether your body stores fat<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\nThat could bring years of anxiety without offering a clear treatment plan. It could also place pressure on memory clinics, scanning facilities, and specialists who are already dealing with patients who have noticeable symptoms.<\/p>\n\n\n\n
Researchers still need to follow people with abnormal markers to learn how many eventually develop dementia. Until those answers arrive, the tests may be most useful for research or for evaluating patients who already report persistent cognitive problems<\/a>.<\/p>\n\n\n\nPrevention may start earlier<\/h2>\n\n\n\n
The findings still carry a practical message. A substantial share of dementia risk is associated with factors that people and health systems may be able to change, including physical inactivity, smoking, depression, poor cardiovascular health, and untreated hearing loss.<\/p>\n\n\n\n
Regular exercise, adequate sleep, social activity, and control of blood pressure or diabetes cannot guarantee total protection. They do support overall brain and heart health<\/a>, and they do not require someone to wait for a new drug or a specialized scan.<\/p>\n\n\n\nBlood testing could eventually become part of a broader risk calculator that combines age, medical history, genetics, lifestyle, and protein levels. Rather than delivering a frightening yes-or-no answer, it might estimate risk and help doctors decide whether more testing<\/a> is worthwhile.<\/p>\n\n\n\nFor the most part, that future has not arrived yet. Still, these studies show that the biological trail of Alzheimer\u2019s may become visible long before the disease takes over everyday life.<\/p>\n\n\n\n
The two official studies were published in <\/a>The Lancet<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"A routine blood draw may one day warn doctors about Alzheimer\u2019s disease years before serious memory problems appear. New research … <\/p>\n
About 6% of the participants had high levels of both types of markers. Those people were still living independently and did not have diagnosable cognitive impairment, but their test results revealed small differences in certain thinking skills.<\/p>\n\n\n\n
Memory risks rose sharply<\/h2>\n\n\n\n
Participants with Alzheimer\u2019s-linked blood markers were more likely to have difficulty with verbal memory, which is the ability to learn and remember words. They also showed differences in processing speed and executive function, skills used when reacting to changing information, organizing a schedule, or managing household finances.<\/p>\n\n\n\n
One amyloid-related marker was associated with more than four times the risk of verbal memory problems. In practical terms, an estimated risk of about three cases in every 100 people could rise to roughly 12 in every 100 among those who tested positive.<\/p>\n\n\n\n
That is a meaningful increase, but it is not a diagnosis. Some people with abnormal proteins may never develop Alzheimer\u2019s dementia, while others may decline years later.<\/p>\n\n\n\n
\u201cAlzheimer\u2019s disease pathology begins years before symptoms emerge,\u201d Yaffe said in a UCSF report. Detecting the process sooner could give people more time to address health factors that may influence dementia risk.<\/p>\n\n\n\n Amyloid is a protein that can form sticky plaques between brain cells. Tau normally helps support the internal structure of those cells, but damaged tau can twist into tangles and interfere with their ability to function.<\/p>\n\n\n\n Think of amyloid as debris beginning to collect along a road. Tau is more closely connected to the traffic breakdown that follows as brain cells become damaged and communication slows.<\/p>\n\n\n\n These changes may begin many years before someone repeatedly loses keys, forgets appointments, or struggles to follow a familiar conversation. That long silent period is why researchers are searching for simple tests that can detect trouble earlier.<\/p>\n\n\n\n A second Lancet study<\/a> compared two radioactive tracers used during positron emission tomography, commonly called PET imaging. Tracers attach to specific proteins and allow a scanner to show where those proteins have accumulated in the brain.<\/p>\n\n\n\n Researchers led by Tharick Pascoal examined 682 participants at eight sites in the United States and Canada. Each person received scans using the established tracer flortaucipir and the experimental tracer MK-6240.<\/p>\n\n\n\n Among cognitively healthy people who already had amyloid buildup, MK-6240 detected tau in about 15%. The standard tracer found it in about 6%, suggesting that the newer method may reveal Alzheimer\u2019s-related changes at an earlier stage.<\/p>\n\n\n\n Current testing can involve expensive brain imaging or a lumbar puncture, which collects fluid from around the spinal cord. Blood tests would be faster, less invasive, and easier to use in regular clinics.<\/p>\n\n\n\n Earlier identification<\/a> could also help doctors decide who may benefit from lecanemab<\/a> or donanemab<\/a>. These drugs do not cure Alzheimer\u2019s or restore memories already lost, but clinical trials indicate that they can modestly slow decline when given during the disease\u2019s early stages.<\/p>\n\n\n\n Timing matters. Once extensive brain damage has occurred, removing some amyloid may offer far less benefit. That is why the search for an early warning test has become one of the field\u2019s biggest priorities.<\/p>\n\n\n\n Should every healthy adult get tested? For now, many specialists say no.<\/p>\n\n\n\n The main problem is uncertainty. Alzheimer\u2019s-linked proteins are relatively uncommon in healthy middle-aged people, and a test could produce false positives or identify people who would never experience serious cognitive decline.<\/p>\n\n\n\n That could bring years of anxiety without offering a clear treatment plan. It could also place pressure on memory clinics, scanning facilities, and specialists who are already dealing with patients who have noticeable symptoms.<\/p>\n\n\n\n Researchers still need to follow people with abnormal markers to learn how many eventually develop dementia. Until those answers arrive, the tests may be most useful for research or for evaluating patients who already report persistent cognitive problems<\/a>.<\/p>\n\n\n\n The findings still carry a practical message. A substantial share of dementia risk is associated with factors that people and health systems may be able to change, including physical inactivity, smoking, depression, poor cardiovascular health, and untreated hearing loss.<\/p>\n\n\n\n Regular exercise, adequate sleep, social activity, and control of blood pressure or diabetes cannot guarantee total protection. They do support overall brain and heart health<\/a>, and they do not require someone to wait for a new drug or a specialized scan.<\/p>\n\n\n\n Blood testing could eventually become part of a broader risk calculator that combines age, medical history, genetics, lifestyle, and protein levels. Rather than delivering a frightening yes-or-no answer, it might estimate risk and help doctors decide whether more testing<\/a> is worthwhile.<\/p>\n\n\n\n For the most part, that future has not arrived yet. Still, these studies show that the biological trail of Alzheimer\u2019s may become visible long before the disease takes over everyday life.<\/p>\n\n\n\n The two official studies were published in <\/a>The Lancet<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" A routine blood draw may one day warn doctors about Alzheimer\u2019s disease years before serious memory problems appear. New research … <\/p>\n
Early detection of Alzheimer’s disease could help families plan care sooner, as researchers investigate blood tests that identify the disease before symptoms appear.<\/figcaption><\/figure>\n\n\n\nWhat these proteins mean<\/h2>\n\n\n\n
Read More: A woman ignored the warning signs for years, then a low-carb diet did something to her type-2 diabetes that surprised her doctors<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
A more sensitive brain scan<\/h2>\n\n\n\n
Why earlier detection matters<\/h2>\n\n\n\n
Screening carries real risks<\/h2>\n\n\n\n
Read More: Scientists studied 49 pairs of identical twins and found a single immune switch that may decide whether your body stores fat<\/a><\/h3>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
Prevention may start earlier<\/h2>\n\n\n\n